Notícias · Recifes

Cancer also knows how to wait: Study uncovers the hidden step between mutation and tumor b

The development of cancer is not a process triggered immediately by the emergence of an oncogenic mutation. There is growing evidence for the existence of an intermediate phase—hitherto poorly defined—in which mutated cells remain in a latent state, "accumulating the potential ne

Admin Recifes 15/07/2026 2

Tumors hijack macrophages after they clear dead cells, real-time tracking reveals

Researchers at Tel Aviv University's Gray Faculty of Medical and Health Sciences have uncovered how a natural and essential immune system process can be hijacked to promote cancer progression. In a new study, the research team developed an advanced technology that enabled it to t

Admin Recifes 15/07/2026 1

Biomarker-matched drug combos shrink treatment-resistant melanoma in preclinical models

A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug combinations based on specific tumor biology to improve outcomes for treatment-resistant advanced melanoma.

Admin Recifes 15/07/2026 2

Two prostate cancer mutations reveal opposite responses to ferroptosis therapy

A new study by researchers at The University of Texas MD Anderson Cancer Center has identified genetic factors that determine whether prostate cancers are susceptible to a type of cell death known as ferroptosis. These findings, published in Nature Communications, could help guid

Admin Recifes 15/07/2026 1

Virus influences rare brain lymphomas, large study finds

Primary CNS lymphoma is a rare cancer that arises from malignant white blood cells. Affected individuals develop tumors in the brain and, more rarely, in the spinal cord, the eyes or within the cerebrospinal fluid. These lymphomas can occur in people with weakened immune systems,

Admin Recifes 15/07/2026 2

Are lung cancer tumors hijacking the nervous system?

According to the Cleveland Clinic, a quarter of cancer deaths can be attributed to one source: cachexia. Cachexia is a syndrome that accompanies underlying chronic illness and causes unwanted muscle and fat loss, reducing quality of life and sometimes even limiting treatment opti

Admin Recifes 15/07/2026 1

New tumor map identifies high-risk B-cell lymphoma standard therapy may miss

Researchers led by Universitätsmedizin Frankfurt and Goethe University Frankfurt have identified how particularly aggressive forms of lymphoma can be recognized. By combining genetic and proteomic analyses, the scientists identified biological characteristics of tumors, particula

Admin Recifes 15/07/2026 1

Forcing cancer cells to die can alert the immune system to enhance anti-tumor attack

Unlike accidental cell death, some cells can actively decide to die through a controlled process. This is called programmed cell death and can occur in different forms, including apoptosis and necroptosis. Cells use this process when they are damaged, stressed, becoming cancerous

Admin Recifes 15/07/2026 1

Common brain cancer mutation changes DNA shape to drive progression, exposing therapeutic

A new study from researchers at The University of Texas MD Anderson Cancer Center has uncovered how one of the most common genetic alterations in glioma rewires the cancer cell genome to fuel tumor progression, suggesting a potential new therapeutic strategy for patients with ATR

Admin Recifes 15/07/2026 2

Platinum TALEN enables mass production of engineered cancer-fighting T cells

Hiroshima University researchers have demonstrated a proof of concept for the mass production of genome-edited T cells that can be used to treat malignant tumors, using a genetic engineering technique called Platinum TALEN.

Admin Recifes 15/07/2026 2

Brain tumor vaccine links mutation targeting to eight-year survival gains

A novel vaccination strategy against certain malignant brain tumors could fundamentally improve treatment for patients. Researchers from the German Cancer Research Center (DKFZ), Mannheim University Medical Center, Heidelberg University Hospital and numerous partner institutions

Admin Recifes 15/07/2026 2

Longer persistence seen with Upadacitinib versus tumor necrosis factor inhibitors in rheum

Patients with rheumatoid arthritis (RA) have longer persistence with upadacitinib than tumor necrosis factor inhibitors (TNFi), according to a study published online June 23 in Rheumatology.

Admin Recifes 15/07/2026 1

Acompanhe as Notícias da Recifes